Almirall confers the 2004 Pharmacology Award
Almirall confers The 2004 Pharmacology Award
Within the field of pharmacology, this award is distinguished for recognising a future research project as opposed to a completed project
Barcelona, 29 September 2004.- Today at the 26th Congress of the Spanish Pharmacology Society that is taking place in Salamanca from 26 to 29 of September, the 2004 Pharmacology Award is being conferred. Jointly promoted by Almirall and the Spanish Pharmacology Society (SEF), it is the first award to recognise the quality of future research projects within the field of pharmacology in Spain.
With a prize of 9,000 euros, the winner project is entitled “Pharmacological implication of the mitochondria in the cellular and molecular routes relating to the Parkinson disease” by Dr Joaquín Jordán, from the University of Castilla la Mancha. The project will be carried out during 2004-2005, and the results will be presented in the next congress of the Spanish Pharmacology Society which will be held in Girona.
The jury has been composed by Dr Felipe Sánchez de la Cuesta, president of SEF, Dr Jesús Llenas and Dr Amadeu Gavaldá. Dr Gavaldá explains: “at the time of valuing this award, we have taken into account, as every year, specially the originality and topicality of the project, its structure, and the difficulty in conducting the study, as well as the new information that could be obtained through its results”.
The evaluation of the projects submitted was carried out through an independent scoring process as well as through consensus among the jury members.
The results of the 2003 Pharmacology Award will be published during the event by Dr Francisco Orallo.
Almirall
The main aim of Almirall is to provide society with innovative drugs to combat discomfort and disease, thus helping to improve health and quality of life. To this end, it constantly devotes the maximum human and financial resources to researching new products.
The company’s main research fields fall within the areas related to the treatment of asthma, allergies, bronchitis, psoriasis, arthritis and gastrointestinal disorders.
The company plans to invest some 500 million euros in R&D during the next five years, and the total sales forecasts for 2004 are projected to reach 956 million euros. Its estimated staff for 2004 is 3.321 people, of whom 518 are related to R&D activities.
The company also has four R&D centres and six manufacturing plants, as well as branch offices in the main cities of Spain and subsidiaries in Europe and Latin America.
Its annual production forecast for this year stands at 88 million units, and products resulting from its own R&D are marketed in over 80 countries around the world.